Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:16 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 50,388 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
176
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 143 more
Conditions
Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
Interventions
Nab-Paclitaxel, Paclitaxel, Docetaxel, Phesgo, T-DM1, Pertuzumab, Trastuzumab Deruxtecan, Trastuzumab Subcutaneous Subcutaneous, Tucatinib, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Kidney Cancer
Interventions
gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Pulmonary Fibrosis, Lung Cancer
Interventions
[68Ga]CBP8, PET Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pancreatic Cancer
Interventions
exatecan mesylate, gemcitabine hydrochloride
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
66
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 59 more
Conditions
Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
Interventions
Carboplatin, Cisplatin, Palbociclib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Triple Negative Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Pancreatic Carcinoma
Interventions
XL888, Pembrolizumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Lung Cancer
Interventions
chromogenic in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, study of socioeconomic and demographic variables, study of high risk factors
Genetic · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
405
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 279 more
Conditions
Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions
²¹²Pb-DOTAM-GRPR1
Drug
Lead sponsor
Orano Med Theranostics, SAS
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more
Conditions
Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
Interventions
Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
Device · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Transrectal Ultrasound-Guided Biopsy, MRI Ultrasound Biopsy, Expanded Prostate Cancer index Composite Questionnaire, Short-Form 12 of Health Related Quality of Life Questionnaire, Memorial Anxiety Scale for Prostate Cancer, Plasma/Serum Sample for biomarkers, Urine Sample for Biomarkers, Blood Tests for Blood Urea Nitrogen and Creatinine, Blood Test for Serum PSA
Procedure · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Miami, Florida
Conditions
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Conditions
Kidney Cancer
Interventions
Aldesleukin,, autologous tumor cell vaccine, recombinant interferon alfa
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Lung Neoplasms
Interventions
pemetrexed, gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
Fort Myers, Florida • Marshfield, Minnesota • Minneapolis, Minnesota + 2 more
Conditions
Lymphoma
Interventions
SAR245409
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Fort Meyers, Florida • Augusta, Georgia + 9 more
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Los Alamitos, California • Torrance, California • Whittier, California + 9 more
Conditions
Pancreatic Trauma, Pancreatic Duct Injury, Pancreas Necrosis, Pancreas Cyst, Pancreas; Fistula, Pancreas Abscess, Intra-Abdominal Abscess, Anastomotic Leak, Pancreas Injury
Interventions
Exploratory laparotomy
Procedure
Lead sponsor
Kern Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bakersfield, California
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes, Metastatic Malignant Neoplasm to the Leptomeninges
Interventions
Intra thecal methotrexate, topotecan, cyclophosphamide
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
Up to 22 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Conditions
Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
3
States / cities
Ithaca, New York • Rochester, New York
Conditions
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Panitumumab, Trametinib
Other · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Amyloid Light-chain Amyloidosis
Interventions
Teclistamab, Daratumumab and Hyaluronidase-fihj
Drug
Lead sponsor
Rajshekhar Chakraborty, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Milwaukee, Wisconsin
Conditions
Breast Cancer, Solid Tumor, Adult
Interventions
APG-2575, Palbociclib
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Austin, Texas • Houston, Texas + 1 more